LymphomaDECIPHERNCT07813585
Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in DLBCL Across the UKCHART Network
An observational study of Lymphoma, run by The Royal Wolverhampton Hospitals NHS Trust.
Trial summary
DECIPHER is a retrospective multicentre observational cohort study using data collected across UKCHART sites. The study will evaluate the impact of ethnicity, socioeconomic deprivation and comorbidity burden on treatment delivery and outcomes in adults diagnosed with DLBCL between 2021 and 2025. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lymphoma
- How many people
- 2,000 participants
- Where
- No sites listed yet
- Study dates
- Oct 2026to Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Data will be collected retrospectively by the 21 individual trusts which make up UKCHART. The population catchment is around 18 million.
Who may be able to join
- Adults aged ≥18 years.
- Newly diagnosed DLBCL.
- Managed within participating UKCHART sites.
Who cannot join
- Transformed lymphoma.
- Insufficient linkage data.
About this study
Official title: DECIPHER - Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in DLBCL Across the UKCHART Network
DECIPHER is a retrospective multicentre observational cohort study using data collected across UKCHART sites. The study will evaluate the impact of ethnicity, socioeconomic deprivation and comorbidity burden on treatment delivery and outcomes in adults diagnosed with DLBCL between 2021 and 2025.
Read the detailed description
Despite the provision of universal healthcare through the National Health Service (NHS), variation in treatment delivery and outcomes among patients with diffuse large B-cell lymphoma (DLBCL) persists. Previous UK population-based studies have demonstrated that socioeconomic factors and multimorbidity influence survival outcomes in aggressive lymphoma, with patients from more deprived backgrounds experiencing poorer outcomes than those from less deprived areas.
Furthermore, multimorbidity has been associated with diagnostic delay and emergency presentation, factors known to adversely affect lymphoma outcomes.
National datasets such as the National Cancer Registration and Analysis Service (NCRAS) and the Systemic Anti-Cancer Therapy (SACT) database provide valuable population-level real-world evidence and have improved understanding of lymphoma outcomes at a national level. However, these datasets often lack the detailed clinical information required to fully explore the impact of ethnicity, socioeconomic deprivation, frailty, comorbidity burden, treatment modifications, and treatment delivery on patient outcomes.
The UK Consortium for Haematology Audit, Real-world Data and Trials (UKCHART) provides a unique opportunity to address these evidence gaps. Through a network of participating NHS organisations serving a large, diverse, and geographically distributed population, UKCHART enables the collection of detailed patient-level clinical data that are not routinely available within national registries. The demographic diversity of the UKCHART population makes it particularly well suited to investigating healthcare inequalities and understanding how ethnicity, deprivation, and comorbidity influence treatment delivery and outcomes in patients with DLBCL.
This study will utilise the UKCHART network to evaluate the impact of ethnicity, socioeconomic deprivation, and comorbidity burden on the delivery of frontline chemoimmunotherapy and subsequent clinical outcomes in patients with newly diagnosed DLBCL. By generating contemporary UK real-world evidence, the study aims to identify potentially modifiable factors contributing to outcome disparities and inform future strategies to improve equity of care for patients with high-grade lymphoma.
- Conditions
- Lymphoma
- Medical subject headings
- Lymphoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment completion
Delivered versus planned number of frontline chemoimmunotherapy cycles
Measured: Time Period between 2021-2026
Dose intensity reduction
Occurrence and magnitude (%) of chemotherapy dose reductions, particularly reductions >25% from planned treatment
Measured: Time Period between 2021-2026
Secondary outcomes (4)
Overall Survival (OS)
Measured as time from diagnosis (or treatment start, as defined in the SAP) to death from any cause
Measured: Time Period between 2021-2026
Progression-Free Survival (PFS)
Measured as time from diagnosis/treatment initiation to disease progression, relapse, or death.
Measured: Time Period between 2021-2026
Stage at Diagnosis
Measured using Ann Arbor stage recorded at diagnosis
Measured: Time Period between 2021-2026
Time to Treatment Initiation
Measured as the interval between diagnosis and commencement of first-line treatment.
Measured: Time Period between 2021-2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2026
- Study startOct 2026 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Royal Wolverhampton Hospitals NHS Trust
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07813585
- Sponsor's protocol ID
- 2026HAE151
- Acronym
- DECIPHER
- Status last verified
- Sep 2026
- First submitted
- 4 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DECIPHER - Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in DLBCL Across the UKCHART Network
- ClinicalTrials.gov ID
- NCT07813585
- Acronym / sponsor ID
- DECIPHER / 2026HAE151
- Conditions
- Lymphoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- The Royal Wolverhampton Hospitals NHS TrustOther government
- Study start
- Oct 2026 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 10 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
DECIPHER is a retrospective multicentre observational cohort study using data collected across UKCHART sites. The study will evaluate the impact of ethnicity, socioeconomic deprivation and comorbidity burden on treatment delivery and outcomes in adults diagnosed with DLBCL between 2021 and 2025.
Detailed description
Despite the provision of universal healthcare through the National Health Service (NHS), variation in treatment delivery and outcomes among patients with diffuse large B-cell lymphoma (DLBCL) persists. Previous UK population-based studies have demonstrated that socioeconomic factors and multimorbidity influence survival outcomes in aggressive lymphoma, with patients from more deprived backgrounds experiencing poorer outcomes than those from less deprived areas.
Furthermore, multimorbidity has been associated with diagnostic delay and emergency presentation, factors known to adversely affect lymphoma outcomes.
National datasets such as the National Cancer Registration and Analysis Service (NCRAS) and the Systemic Anti-Cancer Therapy (SACT) database provide valuable population-level real-world evidence and have improved understanding of lymphoma outcomes at a national level. However, these datasets often lack the detailed clinical information required to fully explore the impact of ethnicity, socioeconomic deprivation, frailty, comorbidity burden, treatment modifications, and treatment delivery on patient outcomes.
The UK Consortium for Haematology Audit, Real-world Data and Trials (UKCHART) provides a unique opportunity to address these evidence gaps. Through a network of participating NHS organisations serving a large, diverse, and geographically distributed population, UKCHART enables the collection of detailed patient-level clinical data that are not routinely available within national registries. The demographic diversity of the UKCHART population makes it particularly well suited to investigating healthcare inequalities and understanding how ethnicity, deprivation, and comorbidity influence treatment delivery and outcomes in patients with DLBCL.
This study will utilise the UKCHART network to evaluate the impact of ethnicity, socioeconomic deprivation, and comorbidity burden on the delivery of frontline chemoimmunotherapy and subsequent clinical outcomes in patients with newly diagnosed DLBCL. By generating contemporary UK real-world evidence, the study aims to identify potentially modifiable factors contributing to outcome disparities and inform future strategies to improve equity of care for patients with high-grade lymphoma.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Data will be collected retrospectively by the 21 individual trusts which make up UKCHART. The population catchment is around 18 million.
Key inclusion criteria (3 listed)
- Adults aged ≥18 years.
- Newly diagnosed DLBCL.
- Managed within participating UKCHART sites.
Key exclusion criteria (2 listed)
- Transformed lymphoma.
- Insufficient linkage data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Treatment completion
Time frame: Time Period between 2021-2026
Delivered versus planned number of frontline chemoimmunotherapy cycles
Dose intensity reduction
Time frame: Time Period between 2021-2026
Occurrence and magnitude (%) of chemotherapy dose reductions, particularly reductions >25% from planned treatment
4 secondary outcomes
Overall Survival (OS)
Time frame: Time Period between 2021-2026
Progression-Free Survival (PFS)
Time frame: Time Period between 2021-2026
Stage at Diagnosis
Time frame: Time Period between 2021-2026
Time to Treatment Initiation
Time frame: Time Period between 2021-2026
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
Related trials for Lymphoma
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Not yet recruitingPhase 1
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Lymphoma, run by The Royal Wolverhampton Hospitals NHS Trust.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment completion (time frame: Time Period between 2021-2026). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.